A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Summary

This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies. The main goals of this study are to: * Identify the recommended dose of AC176 that can be given safely to participants * Evaluate the side effects of AC176 * Evaluate pharmacokinetics of AC176 * Evaluate the effectiveness of AC176

Timeline

Start

2022-03-16

Primary completion

2024-03-05

Completion

2024-03-05

Outcome

Outcome not reported

Stopped: “Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study”

Drugs

Indications